
    
      To assess the effect of intepirdine (RVT-101) versus placebo on quantitative and qualitative
      gait and balance parameters.

      Each subject will be randomized 1:1 to one of the following sequences:

      Sequence 1: AB = RVT-101 35 mg during the early treatment period and Placebo during the late
      treatment period

      Sequence 2: BA = Placebo during the early treatment period and RVT-101 35 mg during the late
      treatment period

      Treatment A = RVT-101 35 mg once daily.

      Treatment B = Placebo once daily.
    
  